Skip to search formSkip to main contentSkip to account menu

Antiparkinson Agents

Known as: antiparkinsonian drugs, ANTI-PARKINSON DRUGS, Antiparkinson Drugs 
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiological functions of the catecholaminergic… 
Highly Cited
2010
Highly Cited
2010
BACKGROUND Deep-brain stimulation is the surgical procedure of choice for patients with advanced Parkinson's disease. The globus… 
Highly Cited
2005
Highly Cited
2005
The reason for the high frequency of depression and anxiety in Parkinson's disease is poorly understood. Degeneration of… 
Highly Cited
2002
Highly Cited
2002
Because little comparative information is available concerning receptor profiles of antiparkinson drugs, affinities of 14 agents… 
Highly Cited
2000
Highly Cited
2000
Hallucinations, mainly of a visual nature, are considered to affect about one-quarter of patients with Parkinson's disease. They… 
Review
1996
Review
1996
  • W. Meck
  • Brain research. Cognitive brain research
  • 1996
  • Corpus ID: 7031554
Review
1993
Review
1993
Highly Cited
1989
Highly Cited
1989
The effects of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that produces the symptoms of Parkinson's… 
Review
1961
Review
1961
  • F. Ayd
  • JAMA
  • 1961
  • Corpus ID: 8768642
Among 3,775 patients treated with tranquilizers of the phenothiazine group, 1,472 developed extrapyramidal reactions; 21.2% had…